Multiple Sclerosis Drug Linked To Many More Cases Of Leukemia
This morning at the American Academy of Neurology’s conference in Seattle, a report was released reporting that there is a significantly increased risk of leukemia from the drug mitoxantrone (Novantrone) in patients with progressive forms of Multiple Sclerosis Drug (MS).Novantrone has always had significant health risks. When patients receive a dosage increase they must undergo regular cardiac monitoring due to the risk of cardiotoxicity and the threat of permanent heart damage.
Today’s report, presented by Dr. Vittorio Martinelli, MD of the University Vita-Salute in Milan, Italy, stated: In a retrospective study of 2,854 Multiple Sclerosis Drug patients receiving the drug, 21 people developed leukemia (.74 percent) and out of those 21, eight patients died.Previously standardized leukemia rates of Novantrone patients were published as .07percent – .25percent.On average, leukemia was reported three years after the first dose of Novantrone and 18 months after drug treatment ended. Number of treatments as well as cumulative dose of the drug seemed to heighten leukemia risk. People developing leukemia had an average of 8.6 doses while those not contracting the disease averaged 7.2 doses.